# WADA Technical Letter – TL2024INDEX

## I. WADA Technical Letters

<table>
<thead>
<tr>
<th>Title</th>
<th>Document Number</th>
<th>Version Number</th>
<th>Effective Date*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meclofenoxate</td>
<td>TL01</td>
<td>4.0</td>
<td>24 November 2021</td>
</tr>
<tr>
<td>Mebeverine Metabolism</td>
<td>TL02</td>
<td>3.0</td>
<td>01 April 2021</td>
</tr>
<tr>
<td>Zeranol</td>
<td>TL04</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Oxilofrine</td>
<td>TL05</td>
<td>3.1</td>
<td>24 November 2021</td>
</tr>
<tr>
<td>Possible Metabolism of Proguanil into Chlorazanil</td>
<td>TL06</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Andarine - Flutamide</td>
<td>TL07</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Use of Internal Standards</td>
<td>TL08</td>
<td>5.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Oxethazaine</td>
<td>TL09</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>In situ Formation of Exogenous Compounds</td>
<td>TL10</td>
<td>3.1</td>
<td>24 November 2021</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>TL11</td>
<td>3.0</td>
<td>01 April 2021</td>
</tr>
<tr>
<td>Enobosarm</td>
<td>TL12</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Substance</td>
<td>TL</td>
<td>Version</td>
<td>Effective Date</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----</td>
<td>---------</td>
<td>------------------</td>
</tr>
<tr>
<td>Trimetazidine</td>
<td>TL13</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Difference in “A” and “B” Sample Urine</td>
<td>TL14</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>TL15</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Tretoquinol</td>
<td>TL16</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Detection of Tulobuterol in the presence of</td>
<td>TL17</td>
<td>3.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Bupropion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testolactone</td>
<td>TL18</td>
<td>2.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Specific substances with a steroid structure</td>
<td>TL20</td>
<td>2.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>6-oxo and metabolites</td>
<td>TL21</td>
<td>2.0</td>
<td>01 January 2021</td>
</tr>
<tr>
<td>Ethylmorphine</td>
<td>TL22</td>
<td>3.0</td>
<td>01 May 2021</td>
</tr>
<tr>
<td>Growth Promoters (meat contaminants)</td>
<td>TL23</td>
<td>1.0</td>
<td>01 June 2021</td>
</tr>
<tr>
<td>Diuretics (contaminants of pharmaceutical</td>
<td>TL24</td>
<td>2.0</td>
<td>24 November 2021</td>
</tr>
<tr>
<td>products)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>TL25</td>
<td>1.0</td>
<td>01 January 2024</td>
</tr>
</tbody>
</table>
II. Recently Approved** Versions of Technical Letters:

<table>
<thead>
<tr>
<th>Title</th>
<th>Document Number</th>
<th>Version Number</th>
<th>Effective Date*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth Promoters (meat contaminants)</td>
<td>TL23</td>
<td>2.0</td>
<td>01 April 2024</td>
</tr>
<tr>
<td>Diuretics (contaminants of pharmaceutical products)</td>
<td>TL24</td>
<td>3.0</td>
<td>01 April 2024</td>
</tr>
</tbody>
</table>

** As per the International Standards for Laboratories, Technical Letters are posted on WADA’s website when approved by the WADA Executive Committee. The newly approved Technical Letters replaces the previous effective version and becomes the mandatory version for all stakeholders by its effective date, which represents the deadline for its mandatory implementation.